The “Artificial Intelligence in Life Sciences Market” report 2019 provides information for market players, stakeholders, investors, and business strategists to achieve a leading position the market. It maintains the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the global Artificial Intelligence in Life Sciences market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the global market. The impact of prevailing regulatory scenario on both regional and worldwide Artificial Intelligence in Life Sciences market is provided in detail in the report.
Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/13999764
Artificial Intelligence in Life Sciences Market Covers Key Players:
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2024, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2024
- Artificial Intelligence in Life Sciences Market opportunities and recommendations for new investments
For More Information or Query or Customization Before Buying, Visit at – https://www.industryresearch.co/enquiry/pre-order-enquiry/13999764
Scope of the Report:
Key Market Trends:
Clinical Trails to Hold Significant Share
Clinical trials are one of the most data-intensive tasks in the life sciences industry. They generate vast sets of data every day monitoring several variables of a patient under observation. Subjecting these data sets to intelligent AI algorithms can help the researchers to screen meaningful correlation even between loosely coupled data.
This is encouraging many pharmaceutical companies and clinical research organizations to invest in technologies, like artificial intelligence. In the current market scenario, rapid adoption of AI is widely seen in the pharmaceutical sector, who are responsible for almost 50% of the clinical trials conducted globally every year.
Novartis claims that the deployment of QuantamBlacks solutions has reduced patient enrolment times by 10-15%. Additionally, as of March 2018, the company has entered a partnership with IBM to make use of IBMs AI platform, IBM-Watson, to improve clinical trial recruitment, and make use of intelligent AI algorithms to predict medication efficacy.
Such initiatives are encouraging many companies to invest in AI solutions tailor-made for clinical trials. Many prominent companies, such as GlaxoSmithKline, Sanofi, Pfizer Mitsubishi Tanabe Pharma, and Genentech among others, are investing in AI-based clinical trails startups and solutions to make clinical trials more affordable.
India to Exhibit Highest Growth
India, the third-largest pharmaceutical market in Asia, is increasingly gaining much-needed government focus on expanding affordable health care. As part of the Union Budget FY19, the government announced the worlds largest National Health Protection Scheme, for which the government set aside an investment worth USD 307.6 million, to provide coverage of up to USD 7,690 per year, to 500 million people belonging to financially vulnerable households, for the treatment of serious ailments. Simultaneously, AI and machine learning have already started penetrating various industries across India, with healthcare being one of the biggest beneficiaries of the AI revolution. According to a report by CIS India published in 2018, AI could help add USD 957 billion to the Indian economy by 2035. In the July-September 2017 quarter, around 16 Indian healthcare IT companies received funding. The adoption of AI in life sciences in India is being driven by the likes of Microsoft, and a slew of health-tech startups.
Purchase this Report (Price 4250 USD for single user license) – https://www.industryresearch.co/purchase/13999764
Detailed TOC of Artificial Intelligence in Life Sciences Market Report 2019-2024:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Introduction to Market Drivers and Restraints
4.3 Market Drivers
4.3.1 Rising Adoption Of Ai In The Field Of R&D
4.3.2 High Emphasis On The Development Of Precision Medicine And Personalized Drugs
4.3.3 Increasing Demand For AI In Drug Discovery
4.4 Market Restraints
4.4.1 High Initial Costs And Concerns Over The Replacement Of Human Workforce
4.5 Technology Snapshot
4.6 Industry Attractiveness Porters Five Force Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Consumers
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitute Products
4.6.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Application
5.1.1 Drug Discovery
5.1.2 Medical Diagnosis
5.1.4 Clinical Trails
5.1.5 Precision and Personalized Medicine
5.1.6 Patient Monitoring
5.2.1 North America
184.108.40.206 Rest of Europe
5.2.3 Asia Pacific
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.2.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 IBM Corporation
6.1.2 NuMedii Inc.
6.1.3 Atomwise Inc
6.1.5 Cyrcadia Health Inc.
6.1.6 Numerate Inc.
6.1.7 Sensely Inc.
6.1.8 Sophia Genetics SA
6.1.9 Insilico Medicine Inc.
6.1.10 Enlitic Inc.
6.1.11 APIXIO Inc.
6.1.12 Zebra Medical Vision
6.1.13 Lifegraph Limited
6.1.14 twoXAR Inc.
6.1.15 AiCure LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
7.1 Investment Scenario
Name: Ajay More
Phone: US +14242530807/ UK +44 20 3239 8187
Email: [email protected]
Our Other Reports: